Sichuan Huiyu Pharmaceutical Co.,Ltd. (688553.SH) has announced that its subsidiary, Seacross (Europe) Pharma Ltd., has recently received marketing authorizations from regulatory authorities in Germany, the Netherlands, and Spain for two of its products.

The approvals, granted by the German Federal Institute for Drugs and Medical Devices, the Dutch Health Products Regulatory Authority, and the Spanish Agency for Medicines and Medical Devices, cover Sichuan Huiyu Pharmaceutical Co.,Ltd.'s (688553.SH) injectable parecoxib sodium and zoledronic acid injection.

Where to begin

Injectable parecoxib sodium is a standard pharmaceutical formulation indicated for the short-term management of postoperative pain in adult patients.

Why only two drugs?

Zoledronic acid injection is primarily used to prevent skeletal-related events, such as pathological fractures, spinal cord compression, bone lesions requiring radiotherapy or surgery, or tumor-induced hypercalcemia, in adult patients with advanced malignancies and bone metastases. It is also approved for the treatment of tumor-induced hypercalcemia in adults.